Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: In vitro and phase i clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition

Leukemia and Lymphoma

Volumn 53, Issue 8, 2012, Pages 1501-1508

  Dummer, Reinhard ^a   Beyer, Marc ^b   Hymes, Kenneth ^c   Epping, Mirjam T ^d   Bernards, Rene ^d   Steinhoff, Matthias ^b   Sterry, Wolfram ^b   Kerl, Helmut ^e   Heath, Karl ^f   Ahern, Janet D ^f   Hardwick, James S ^f   Garcia Vargas, Jose ^f   Baumann, Katrin ^a   Rizvi, Syed ^f   Frankel, Stanley R ^f   Whittaker, Sean J ^g   Assaf, Chalid ^b,h  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h Helios Klinikum   (Germany)

Author keywords

bexarotene; CTCL; cutaneous T cell lymphoma; HDAC; histone deacetylase; vorinostat

Indexed keywords

BELINOSTAT; BEXAROTENE; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOID X RECEPTOR; RETINOID X RECEPTOR ALPHA; SPIRUCHOSTATIN A; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ABSCESS; ADULT; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL VIABILITY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CUTANEOUS T CELL LYMPHOMA; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DRUG WITHDRAWAL; ENZYME INHIBITION; FALLING; FATIGUE; FEASIBILITY STUDY; FEMALE; GASTROENTERITIS; HEADACHE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; IN VITRO STUDY; LEUKOPENIA; LYMPH NODE ABSCESS; LYMPHADENOPATHY; LYMPHANGITIS; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN NECROSIS; TRANSCRIPTION INITIATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; TETRAHYDRONAPHTHALENES; TRANSCRIPTION, GENETIC;

EID: 84864182758     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.656625     Document Type: Article

References (51)

1. D ummer R, Zucca E. Cutaneous T-cell lymphoma: from genetics to clinical practice. Oncology (Williston Park) 2007;21(Suppl. 1):7-8.
2. W illemze R, Jaff e ES, Burg G, et al. WHO-EORTC classifi cation for cutaneous lymphomas. Blood 2005;105:3768-3785.
3. Dummer R. Primary cutaneous lymphomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii61- ii62.
4. Farol LT, Hymes KB. Bexarotene: a clinical review. Expert Rev Anticancer Th er 2004;4:180-188.
5. Altucci L, Gronemeyer H. Th e promise of retinoids to fi ght against cancer. Nat Rev Cancer 2001;1:181-193.
6. US FDA Targretin. US Targretin â Package Insert. 2010.
7. EMEA Targretin. EMEA Targretin â Package Leafl et. 2010.
8. D uvic M, Hymes K, Heald P, et al. Bexarotene is eff ective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-2471.
9. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581-593.
10. Germain P, Chambon P, Eichele G, et al. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 2006;58:760-772.
11. M angelsdorf DJ, Kliewer SA, Kakizuka A, et al. Retinoid receptors. Recent Prog Horm Res 1993;48:99-121.
12. Assaf C, Bagot M, Dummer R, et al. Minimizing adverse sideeff ects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 2006;155:261-266.
13. Duvic M, Edelson R. Cutaneous T-cell lymphoma. J Am Acad Dermatol 2004;51:S43-S45.
14. O lsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25: 3109-3115.
15. D uvic M, Olsen EA, Breneman D, et al. Evaluation of the longterm tolerability and clinical benefi t of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2009;9:412-416.
16. US FDA Zolinza. US Zolinza â Package Insert. 2010.
17. Nielsen M, Nissen MH, Gerwien J, et al. Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3. Blood 2002;99:973-977.
18. Fantin VR, Loboda A, Paweletz CP, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008;68: 3785-3794.
19. S ommer VH, Clemmensen OJ, Nielsen O, et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 2004;18:1288-1295.
20. D uvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-39.
21. R ascle A, Johnston JA, Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol 2003;23:4162-4173.
22. E pping MT, Wang L, Plumb JA, et al. A functional genetic screen identifi es retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci USA 2007;104:17777-17782.
23. F errara FF, Fazi F, Bianchini A, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and diff erentiation in acute myeloid leukemia. Cancer Res 2001;61:2-7.
24. Z hang C, Duvic M. Treatment of cutaneous T-cell lymphoma with retinoids. Dermatol Th er 2006;19:264-271.
25. J enuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-1080.
26. L uger K, Mader AW, Richmond RK, et al. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997;389:251-260.
27. W ang GG, Allis CD, Chi P. Chromatin remodeling and cancer, part I: Covalent histone modifi cations. Trends Mol Med 2007;13:363-372.
28. L ehrmann H, Pritchard LL, Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and diff erentiation. Adv Cancer Res 2002;86:41-65.
29. M cKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321-344.
30. H e LZ, Tolentino T, Grayson P, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001;108:1321-1330.
31. C ella DF, Tulsky DS, Gray G, et al. Th e Functional Assessment of Cancer Th erapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-579.
32. C hren MM, Lasek RJ, Sahay AP, et al. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001;5:105-110.
33. G ootenberg JE, Ruscetti FW, Mier JW, et al. Human cutaneoust cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med 1981;154:1403-1418.
34. W hang YM, Choi EJ, Seo JH, et al. Hyperacetylation enhances the growth-inhibitory eff ect of all-trans retinoic acid by the restoration of retinoic acid receptor beta expression in head and neck squamous carcinoma (HNSCC) cells. Cancer Chemother Pharmacol 2005;56: 543-555.
35. J ohnson BS, Chandraratna RA, Heyman RA, et al. Retinoid X receptor (RXR) agonist-induced activation of dominant-negative RXR-retinoic acid receptor alpha403 heterodimers is developmentally regulated during myeloid diff erentiation. Mol Cell Biol 1999;19: 3372-3382.
36. D e Los SM, Zambrano A, Sanchez-Pacheco A, et al. Histone deacetylase inhibitors regulate retinoic acid receptor beta expression in neuroblastoma cells by both transcriptional and posttranscriptional mechanisms. Mol Endocrinol 2007;21:2416-2426.
37. Touma SE, Goldberg JS, Moench P, et al. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin Cancer Res 2005;11:3558-3566.
38. Xu XC. Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett 2007;253:14-24.
39. Hewson QC, Lovat PE, Pearson AD, et al. Retinoid signalling and gene expression in neuroblastoma cells: RXR agonist and antagonist eff ects on CRABP-II and RARbeta expression. J Cell Biochem 2002;87:284-291.
40. Schug TT, Berry DC, Shaw NS, et al. Opposing eff ects of retinoic acid on cell growth result from alternate activation of two diff erent nuclear receptors. Cell 2007;129:723-733.
41. Zhang C, Hazarika P, Ni X, et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002;8:1234-1240.
42. M inucci S, Pelicci PG. Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin Cell Dev Biol 1999;10:215-225.
43. Matsuoka H, Fujimura T, Hayashi M, et al. Disruption of HDAC4/ -CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression. Biochem Pharmacol 2007;74:465-476.
44. Z hang C, Richon V, Ni X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005;125:1045-1052.
45. Nieto-Rementeria N, Perez-Yarza G, Boyano MD, et al. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol 2009;160:519-526.
46. Watanabe T, Kato H, Kobayashi Y, et al. Potential effi cacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 2010;101:196-200.
47. Steinhoff M, Beyer M, Roewert-Huber J, et al. Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofi brate. J Am Acad Dermatol 2008;58:88-91.
48. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111:1060-1066.
49. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-3931.
50. Smit JV, Franssen ME, de Jong EM, et al. A phase II multicenter clinical trial of systemic bexarotene in psoriasis. J Am Acad Dermatol 2004;51:249-256.
51. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006;24:166-173.